Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE

Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE - HeartFlow ADVANCE Registry

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032186

Enrollment

7500

Registered

2018-04-16

Start date

2015-07-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Diseases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Provide written informed consent 2. Clinically stable, symptomatic patients who undergo cCTA and are diagnosed with CAD and meet eligibility criteria for FFRCT.

Exclusion criteria

Exclusion criteria: 1. cCTA showing no CAD 2. Uninterpretable cCTA by site assessment, in which severe artifacts prevent angiographic evaluation 3. Any active, serious, life-threatening disease with a life expectancy of less than 1 year 4. Inability to comply with follow-up requirements

Design outcomes

Primary

Measure	Time frame
The primary endpoint of the ADVANCE Registry is the reclassification rate between the coronary management plan based on the review of the cCTA compared to the management plan based on FFRCT when obtained, as assessed by an independent review committee.	—

Countries

Japan,North America,Europe

Contacts

Public ContactReiko Masui

HeartFlow Japan Clinical Affairs

rmasui@heartflow.com03-3539-3730

Outcome results